Associations - Microtubule inhibitor

No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: A1 - Approval ado-trastuzumab emtansine Sensitive : A1	ado-trastuzumab emtansine Sensitive: A1 - Approval ado-trastuzumab emtansine Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	cabazitaxel Sensitive: A1 - Approval cabazitaxel Sensitive : A1	cabazitaxel Sensitive: A1 - Approval cabazitaxel Sensitive : A1
TNFRSF8 positive	Hodgkin Lymphoma	TNFRSF8 positive	Hodgkin Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	rituximab + polatuzumab vedotin-piiq Sensitive: A1 - Approval rituximab + polatuzumab vedotin-piiq Sensitive : A1	rituximab + polatuzumab vedotin-piiq Sensitive: A1 - Approval rituximab + polatuzumab vedotin-piiq Sensitive : A1
TNFRSF8 positive	Cutaneous T-cell Lymphoma	TNFRSF8 positive	Cutaneous T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Liposarcoma	No biomarker	Liposarcoma	eribulin mesylate Sensitive: A1 - Approval eribulin mesylate Sensitive : A1	eribulin mesylate Sensitive: A1 - Approval eribulin mesylate Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	eribulin mesylate Sensitive: A1 - Approval eribulin mesylate Sensitive : A1	eribulin mesylate Sensitive: A1 - Approval eribulin mesylate Sensitive : A1
TNFRSF8 expression	Peripheral T-cell Lymphoma	TNFRSF8 expression	Peripheral T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	belantamab mafodotin-blmf Sensitive: A1 - Approval belantamab mafodotin-blmf Sensitive : A1	belantamab mafodotin-blmf Sensitive: A1 - Approval belantamab mafodotin-blmf Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	polatuzumab vedotin-piiq Sensitive: A1 - Approval polatuzumab vedotin-piiq Sensitive : A1	polatuzumab vedotin-piiq Sensitive: A1 - Approval polatuzumab vedotin-piiq Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	ixabepilone Sensitive: A1 - Approval ixabepilone Sensitive : A1	ixabepilone Sensitive: A1 - Approval ixabepilone Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: A1 - Approval enfortumab vedotin-ejfv Sensitive : A1	enfortumab vedotin-ejfv Sensitive: A1 - Approval enfortumab vedotin-ejfv Sensitive : A1
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	tisotumab vedotin-tftv Sensitive: A1 - Approval tisotumab vedotin-tftv Sensitive : A1	tisotumab vedotin-tftv Sensitive: A1 - Approval tisotumab vedotin-tftv Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	disitamab vedotin Sensitive: A1 - Approval disitamab vedotin Sensitive : A1	disitamab vedotin Sensitive: A1 - Approval disitamab vedotin Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	disitamab vedotin Sensitive: A1 - Approval disitamab vedotin Sensitive : A1	disitamab vedotin Sensitive: A1 - Approval disitamab vedotin Sensitive : A1
FOLR1 positive	Ovarian Cancer	FOLR1 positive	Ovarian Cancer	bevacizumab + mirvetuximab soravtansine-gynx Sensitive: A1 - Approval bevacizumab + mirvetuximab soravtansine-gynx Sensitive : A1	bevacizumab + mirvetuximab soravtansine-gynx Sensitive: A1 - Approval bevacizumab + mirvetuximab soravtansine-gynx Sensitive : A1
FOLR1 positive	Peritoneal Cancer	FOLR1 positive	Peritoneal Cancer	mirvetuximab soravtansine-gynx Sensitive: A1 - Approval mirvetuximab soravtansine-gynx Sensitive : A1	mirvetuximab soravtansine-gynx Sensitive: A1 - Approval mirvetuximab soravtansine-gynx Sensitive : A1
FOLR1 positive	Fallopian Tube Cancer	FOLR1 positive	Fallopian Tube Cancer	mirvetuximab soravtansine-gynx Sensitive: A1 - Approval mirvetuximab soravtansine-gynx Sensitive : A1	mirvetuximab soravtansine-gynx Sensitive: A1 - Approval mirvetuximab soravtansine-gynx Sensitive : A1
FOLR1 positive	Ovarian Cancer	FOLR1 positive	Ovarian Cancer	mirvetuximab soravtansine-gynx Sensitive: A1 - Approval mirvetuximab soravtansine-gynx Sensitive : A1	mirvetuximab soravtansine-gynx Sensitive: A1 - Approval mirvetuximab soravtansine-gynx Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	pembrolizumab + enfortumab vedotin-ejfv Sensitive: A1 - Approval pembrolizumab + enfortumab vedotin-ejfv Sensitive : A1	pembrolizumab + enfortumab vedotin-ejfv Sensitive: A1 - Approval pembrolizumab + enfortumab vedotin-ejfv Sensitive : A1
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	nivolumab + brentuximab vedotin Sensitive: A2 - Guideline nivolumab + brentuximab vedotin Sensitive : A2	nivolumab + brentuximab vedotin Sensitive: A2 - Guideline nivolumab + brentuximab vedotin Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	ixabepilone Sensitive: A2 - Guideline ixabepilone Sensitive : A2	ixabepilone Sensitive: A2 - Guideline ixabepilone Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	enfortumab vedotin-ejfv Sensitive: A2 - Guideline enfortumab vedotin-ejfv Sensitive : A2	enfortumab vedotin-ejfv Sensitive: A2 - Guideline enfortumab vedotin-ejfv Sensitive : A2
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
No biomarker	Leiomyosarcoma	No biomarker	Leiomyosarcoma	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
TNFRSF8 positive	Diffuse Large B Cell Lymphoma	TNFRSF8 positive	Diffuse Large B Cell Lymphoma	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2

Microtubule inhibitor

Microtubule inhibitor

Associations(530)

Associations
(530)